Our objectives were to assess survival and predictors for survival among @entity706 @entity1 whose disease had progressed after autologous bone marrow (ABMT) or stem cell transplantation (ASCT). @entity1 transplanted at Hadassah University Hospital between October 1983 and February 1999 were included. We compared survival of @entity1 with @entity978 ( @entity978 ) and @entity1893 ( @entity1893 ) after relapse or progression. Predictors for survival were assessed in a multivariate model. Of 88 transplanted @entity1 with @entity978 and 152 with @entity1893 , relapse/progression occurred in 27 (31%) and 75 (49%), respectively. Median survival postrelapse was 25 months for @entity978 and 7.5 months for @entity1893 (P=0.12). Seven relapsed @entity1 with @entity978 (26%) and 10 (13%) with @entity1893 survived >4 years. In @entity1893 , longer postrelapse survival was associated with indolent histologies (P=0.007). On multivariate analysis, factors associated with survival included attainment of remission postrelapse (for both diseases), use of prophylactic immunotherapy (for @entity978 ), LDH level and time from transplant to relapse (for @entity1893 ). The short-term prognosis for @entity1 with disease progression postautologous transplant may be somewhat better for @entity978 compared to @entity1893 . Long-term survival is poor in both diseases. However, the survival times in the current study are twice as long as those previously reported. Treatment regimens with the potential for achieving remission may have an impact on survival.

Factors associated with survival in @entity1 with progressive disease following autologous transplant for XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity978 :: ('MESH:D006689', 'Disease') :: ['HD', "Hodgkin's disease"] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma'] @entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphoma", 'NHL']
@entity706 :: (MESH:D008223,Disease) :: ['lymphoma']
